HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sports Supplements: Medicine or Food? Australia Debates

Executive Summary

Following a string of cases in Australia in which illegal prescription medicines and toxic or dangerous substances have been found in sports supplements, the country's medicines agency is consulting on whether these products should be in future regulated as medicines.  

You may also be interested in...



Australia Finds ‘Unacceptable’ Levels Of NDMA In 80% of Ranitidine Batches

Testing carried out by Australia's drug agency on batches of 34 ranitidine products marketed by 10 different sponsors has found high levels of NDMA contamination in the vast majority of cases. The agency is now considering tightening its oversight of all ranitidine drugs sold in Australia. 

Australia Rejects Hair-Loss Switch, Up-Schedules Modified-Release Paracetamol

Australia has rejected an application to switch an oral hair-loss treatment, while also up-scheduling modified release paracetamol over safety concerns.

Australia Introduces ‘Appendix M’ Criteria To Facilitate Innovative Switches

Australia's Therapeutic Goods Administration has introduced a set of criteria introducing additional controls for medicines rescheduled from ‘Schedule 4’ (prescription-only) to ‘Schedule 3’ (non-prescription, pharmacist-only) status, intended to facilitate more innovative prescription-to-OTC switches in the future.

Related Content

Topics

UsernamePublicRestriction

Register

RS149409

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel